This intervention is developed to monitor individuals undergoing treatment and overcome the difficulties in validating self-reported feedback.
Based on the Discrete Element Method (DEM), a bonded sphero-cylinder model is developed to simulate flexible fibers that can undergo plastic bending deformation.
Therefore, the nanoplatform-based camptothecin (S-CKD-602 [ 69] and CRLX101 [ 70]) and irinotecan (SN-38, NK012 [ 71]) are developed undergoing clinical trials.
EndoTAG-1 [ 57], LEP-ETU [ 58], Genexol-PM [ 59], NK105 [ 60], and Opaxio [ 61] are developed as paclitaxel-loaded nanoplatforms undergoing clinical trials.
Clinical dehydration scale (CDS) has been developed and undergone validation for measuring dehydration in children.
Several fluoroquinolone preparations are on market all over the world, while a number of new compounds are presently being developed or undergoing clinical studies.
More recent work using thymidine analogs labeled with F (half-life 109 minutes) have been developed and undergone considerable advances in recent years [ 63, 64].
In the case of the latter, a PARP inhibitor, olaparib (AstraZeneca) has already been developed and undergone successful clinical trials [ 54].
More specific and targeted MRI agents have also been developed and undergone preliminary testing [ 18]; however, the range of possible molecular agents is somewhat constrained by the need to include a magnetically active atom such as Gd or Fe.
A reference method employing a specially-designed chamber has been developed and is undergoing extensive evaluation.
